Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

NCT05582499 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

716

Enrollment

OTHER

Sponsor class

Conditions

Breast Neoplasm
Breast Cancer
Breast Tumors
Triple-Negative Breast Cancer (TNBC)
HER2-positive Breast Cancer
HER2-negative Breast Cancer
Hormone Receptor Positive Tumor
Hormone Receptor Negative Tumor
Early-stage Breast Cancer
Locally Advanced Breast Cancer

Interventions

DRUG: Dalpiciclib
DRUG: Pyrotinib
DRUG: SHR-A1811
DRUG: SHR-1316
DRUG: Camrelizumab
DRUG: SHR-A1921
DRUG: Pertuzumab
DRUG: Trastuzumab
DRUG: Goserelin
DRUG: Letrozole
DRUG: Nab paclitaxel
DRUG: Carboplatin
DRUG: Epirubicin
DRUG: Cyclophosphamide
DRUG: Fluzoparib
DRUG: Apatinib
DRUG: Famitinib
DRUG: HB1801
DRUG: LEM
DRUG: TQB2102

Sponsor

Fudan University